Target family: Other pattern recognition receptors (type: other_protein)
Target: stimulator of interferon response cGAMP interactor 1

Ligand: STING agonist 3 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Journal): Design of amidobenzimidazole STING receptor agonists with systemic activity.
Published in: Nature

Ligand: ulevostinag (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 10.699999809265137 pKd
Reference (Journal): Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
Published in: J Med Chem

Ligand: ulevostinag (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.529999732971191 pKd
Reference (Journal): Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
Published in: J Med Chem

Ligand: diABZI-4 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Patent): Heterocyclic amides useful as protein modulators.

Ligand: H-151 (Synthetic organic)
Interaction type: Antagonist
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Targeting STING with covalent small-molecule inhibitors.
Published in: Nature

Ligand: SNX281 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.389999866485596 pIC50
Reference (Journal): Design of a systemic small molecule clinical STING agonist using physics-based simulations and artificial intelligence
Published in: biorxiv

Ligand: STING agonist 2 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity: 8.800000190734863 pKd
Reference (Journal): Design of amidobenzimidazole STING receptor agonists with systemic activity.
Published in: Nature

Ligand: 2'3'-cGAMP (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING.
Published in: Mol Cell

Ligand: ADU-S100 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.
Published in: Cell Rep

Ligand: compound 40 [PMID: 33470814] (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.619999885559082 pEC50
Reference (Journal): Structure-Activity Relationship Study of Amidobenzimidazole Analogues Leading to Potent and Systemically Administrable Stimulator of Interferon Gene (STING) Agonists.
Published in: J Med Chem

Ligand: compound 53 [PMID: 33038794] (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.730000019073486 pEC50
Reference (Journal): The discovery of potent small molecule activators of human STING.
Published in: Eur J Med Chem

Ligand: cyclic di-GMP (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): STING is a direct innate immune sensor of cyclic di-GMP.
Published in: Nature